Movement Alert｜WUXI XDC Rises 3.07% in Regular Trading, Interim Results Expectations Heat Up as CXO Sector Strengthens

Market Focus

Aug 07

On August 7, WUXI XDC rose 3.07% in regular trading, trading at HKD 57.2/share, with turnover of HKD 36.63 million. The rally was driven by rising expectations ahead of the company's interim results review scheduled for August 24, combined with broad-based CXO sector strength.

On the news front, CLSA previously raised its target price on WUXI XDC to HKD 82.6, maintaining an Outperform rating, forecasting revenue and adjusted net profit growth to exceed guidance. Daiwa initiated coverage with a Buy rating and HKD 78 target price, naming the company a top pick in China's CXO industry, citing its 24% global ADC outsourcing market share and full-chain CRDMO capabilities.

Sector linkage effects remained pronounced on the same day, with Pharmaron up 6.12%, Wuxi AppTec up 3.9%, and Wuxi Bio up 3.72%. Global biotech financing recovery and robust ADC R&D investment continued to drive pre-positioning by institutional capital.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1118233678"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1118233678\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1118233678?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 09:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118233678","market":"us","top_or_hot":-1,"title":"Movement Alert｜WUXI XDC Rises 3.07% in Regular Trading, Interim Results Expectations Heat Up as CXO Sector Strengthens","media":"Market Focus","content":"<p><p>On August 7, WUXI XDC rose 3.07% in regular trading, trading at HKD 57.2/share, with turnover of HKD 36.63 million. The rally was driven by rising expectations ahead of the company's interim results review scheduled for August 24, combined with broad-based CXO sector strength.</p><p>On the news front, CLSA previously raised its target price on WUXI XDC to HKD 82.6, maintaining an Outperform rating, forecasting revenue and adjusted net profit growth to exceed guidance. Daiwa initiated coverage with a Buy rating and HKD 78 target price, naming the company a top pick in China's CXO industry, citing its 24% global ADC outsourcing market share and full-chain CRDMO capabilities.</p><p>Sector linkage effects remained pronounced on the same day, with Pharmaron up 6.12%, Wuxi AppTec up 3.9%, and Wuxi Bio up 3.72%. Global biotech financing recovery and robust ADC R&D investment continued to drive pre-positioning by institutional capital.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜WUXI XDC Rises 3.07% in Regular Trading, Interim Results Expectations Heat Up as CXO Sector Strengthens</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜WUXI XDC Rises 3.07% in Regular Trading, Interim Results Expectations Heat Up as CXO Sector Strengthens\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-07 09:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 7, WUXI XDC rose 3.07% in regular trading, trading at HKD 57.2/share, with turnover of HKD 36.63 million. The rally was driven by rising expectations ahead of the company's interim results review scheduled for August 24, combined with broad-based CXO sector strength.</p><p>On the news front, CLSA previously raised its target price on WUXI XDC to HKD 82.6, maintaining an Outperform rating, forecasting revenue and adjusted net profit growth to exceed guidance. Daiwa initiated coverage with a Buy rating and HKD 78 target price, naming the company a top pick in China's CXO industry, citing its 24% global ADC outsourcing market share and full-chain CRDMO capabilities.</p><p>Sector linkage effects remained pronounced on the same day, with Pharmaron up 6.12%, Wuxi AppTec up 3.9%, and Wuxi Bio up 3.72%. Global biotech financing recovery and robust ADC R&D investment continued to drive pre-positioning by institutional capital.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02268","symbol_name":"药明合联","start_time":0,"source_url":"","article_id":"1118233678","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118233678","pubTimestamp":1786067264,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 7, WUXI XDC rose 3.07% in regular trading, trading at HKD 57.2/share, with turnover of HKD 36.63 million. The rally was driven by rising expectations ahead of the company's interim results...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02268":"药明合联"},"translate_title":"走势提醒|无锡XDC常规交易上涨3.07%，CXO板块走强，中期业绩预期升温","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02268":1},"content_text":"On August 7, WUXI XDC rose 3.07% in regular trading, trading at HKD 57.2/share, with turnover of HKD 36.63 million. The rally was driven by rising expectations ahead of the company's interim results review scheduled for August 24, combined with broad-based CXO sector strength.On the news front, CLSA previously raised its target price on WUXI XDC to HKD 82.6, maintaining an Outperform rating, forecasting revenue and adjusted net profit growth to exceed guidance. Daiwa initiated coverage with a Buy rating and HKD 78 target price, naming the company a top pick in China's CXO industry, citing its 24% global ADC outsourcing market share and full-chain CRDMO capabilities.Sector linkage effects remained pronounced on the same day, with Pharmaron up 6.12%, Wuxi AppTec up 3.9%, and Wuxi Bio up 3.72%. Global biotech financing recovery and robust ADC R&D investment continued to drive pre-positioning by institutional capital.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}